Jupiter Neurosciences Inc
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.
Current Price
$0.24
+16.93%Jupiter Neurosciences Inc (JUNS) Stock News
JUNS Stock News & Headlines
Latest stock news and headlines for Jupiter Neurosciences Inc (JUNS). Stay informed on earnings reports, analyst upgrades and downgrades, market-moving events, and company announcements.
Current stock price: $0.24. Market cap: $7.06M. Sector: Healthcare. Industry: Biotechnology. This page aggregates the latest news articles relevant to JUNS from financial news sources, helping investors stay current on events that may impact Jupiter Neurosciences Inc's stock price.
News catalysts can drive significant short-term price movement. Earnings surprises, management changes, product launches, regulatory decisions, and analyst coverage changes all create opportunities and risks. Combine news monitoring with GoodMoat's fundamental analysis, quality scores, and valuation tools for a complete research workflow on Jupiter Neurosciences Inc (JUNS).